These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 26052195)

  • 21. Association of Real-time Continuous Glucose Monitoring With Glycemic Control and Acute Metabolic Events Among Patients With Insulin-Treated Diabetes.
    Karter AJ; Parker MM; Moffet HH; Gilliam LK; Dlott R
    JAMA; 2021 Jun; 325(22):2273-2284. PubMed ID: 34077502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
    Turner RC; Cull CA; Frighi V; Holman RR
    JAMA; 1999 Jun; 281(21):2005-12. PubMed ID: 10359389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glycemic control after initiating basal insulin therapy in patients with type 2 diabetes: a primary care database analysis.
    Kostev K; Dippel FW; Rathmann W
    Diabetes Metab Syndr Obes; 2015; 8():45-8. PubMed ID: 25609990
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Delays in Insulin Initiation among Patients with Type 2 Diabetes Mellitus in Southeast China: A Retrospective, Real-World Study.
    Chen P; Ma X; Chen H; Wang K; Zhou L
    Diabetes Metab Syndr Obes; 2020; 13():3059-3068. PubMed ID: 32922056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
    Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
    Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EADSG Guidelines: Insulin Therapy in Diabetes.
    Silver B; Ramaiya K; Andrew SB; Fredrick O; Bajaj S; Kalra S; Charlotte BM; Claudine K; Makhoba A
    Diabetes Ther; 2018 Apr; 9(2):449-492. PubMed ID: 29508275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of Combined Tofogliflozin and Glargine, Tofogliflozin Added to Insulin, and Insulin Dose-Increase Therapy in Uncontrolled Type 2 Diabetes.
    Suzuki K; Mitsuma Y; Sato T; Anraku T; Hatta M
    J Clin Med Res; 2016 Nov; 8(11):805-814. PubMed ID: 27738482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes and treatment patterns of adding a third agent to 2 OADs in patients with type 2 diabetes.
    Levin PA; Wei W; Zhou S; Xie L; Baser O
    J Manag Care Spec Pharm; 2014 May; 20(5):501-12. PubMed ID: 24761822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can an electronic glycaemic notebook associated with an insulin calculator improve HbA1c in diabetic patients on a multiple insulin injections regimen? A 26-week observational real-life study.
    Oriot P; Ponchon M; Hermans MP
    Acta Clin Belg; 2016 Feb; 71(1):51-6. PubMed ID: 27150670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes.
    Nicolucci A; Ceriello A; Di Bartolo P; Corcos A; Orsini Federici M
    Diabetes Ther; 2020 Mar; 11(3):573-584. PubMed ID: 31873857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of time to treatment intensification on glycemic goal attainment among patients with type 2 diabetes failing metformin monotherapy.
    Rajpathak SN; Rajgopalan S; Engel SS
    J Diabetes Complications; 2014; 28(6):831-5. PubMed ID: 25104238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of response to insulin therapy in youth with poorly-controlled type 2 diabetes in the TODAY trial.
    Bacha F; El Ghormli L; Arslanian S; Zeitler P; Laffel LM; Levitt Katz LE; Gandica R; Chang NT; Sprague JE; Macleish SA;
    Pediatr Diabetes; 2019 Nov; 20(7):871-879. PubMed ID: 31418516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and Economic Outcomes of Patients with Type 2 Diabetes on Multiple Daily Injections of Basal-bolus Insulin (MDI) Therapy: A Retrospective Cohort Study.
    Brixner D; Ermakova A; Xiong Y; Sieradzan R; Sacks N; Cyr P; Taylor SD
    Clin Ther; 2019 Feb; 41(2):303-313.e1. PubMed ID: 30709610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Slow Titration and Delayed Intensification of Basal Insulin Among Patients with Type 2 Diabetes.
    Mocarski M; Yeaw J; Divino V; DeKoven M; Guerrero G; Langer J; Thorsted BL
    J Manag Care Spec Pharm; 2018 Apr; 24(4):390-400. PubMed ID: 29406841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does the timing of insulin pump therapy initiation after type 1 diabetes onset have an impact on glycemic control?
    Shalitin S; Lahav-Ritte T; Lebenthal Y; Devries L; Phillip M
    Diabetes Technol Ther; 2012 May; 14(5):389-97. PubMed ID: 22283639
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM).
    Abraira C; Henderson WG; Colwell JA; Nuttall FQ; Comstock JP; Emanuele NV; Levin SR; Sawin CT; Silbert CK
    Diabetes Care; 1998 Apr; 21(4):574-9. PubMed ID: 9571345
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does Preoperative Glycemic Control Restore Immune Defense Against Implant-related Infection in Mice With Diabetes?
    Lin J; Huang T; Wei H; Bao B; Gao T; Zheng X; Zhu H
    Clin Orthop Relat Res; 2022 May; 480(5):1008-1017. PubMed ID: 34797251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S; Koenen C; Bode B
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical characteristics of type 2 diabetic patients on basal insulin therapy with adequate fasting glucose control who do not achieve HbA1c targets.
    Mata-Cases M; Mauricio D; Franch-Nadal J
    J Diabetes; 2017 Jan; 9(1):34-44. PubMed ID: 26749415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Individualized HbA
    Lautsch D; Boggs R; Wang T; Gonzalez C; Milligan G; Rajpathak S; Malkani S; McLeod E; Carroll J; Higgins V
    Adv Ther; 2022 Feb; 39(2):1016-1032. PubMed ID: 34951678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.